Table 4.

Incidence rates and hazard ratios of vancomycin compared to all comparators and vancomycin compared to singular comparator, restricted to a cohort with at least 5 days of antibiotic treatment.

	N	Cases	Person timeb	Incidence rateb	95% CI	Crude HR	95% CI	Adjusted HRc	95% CI
Vancomycina	2959	14	12.41	1.13	0.67–1.91
Comparators	10,652	63	44.61	1.41	0.10–1.81	0.80	0.45–1.43	0.62	0.34–1.15
Cefazolin	6426	26	26.97	0.96	0.66–1.42	1.17	0.61–2.24	0.84	0.38–1.83
Linezolid	210	6	0.87	6.91	3.11–15.39	0.16	0.06–0.43	0.13	0.05–0.40
Piperacillin	2097	20	8.74	2.29	1.48–3.55	0.49	0.25–0.98	0.35	0.15–0.82
Cefepime	276	1	1.15	0.87	0.12–6.18	1.30	0.17–9.86	1.23	0.13–11.39
Meropenem	278	4	1.16	3.44	2.29–9.16	0.33	0.11–1.00	0.34	0.10–1.20
Ertapenem	1174	5	4.92	1.02	0.42–2.44	1.11	0.40–3.1	0.40	0.12–1.27
Daptomycin	191	1	0.80	1.25	0.18–8.90	0.90	0.12–6.85	0.68	0.08–5.81

95% CI 95% confidence interval, HR hazard ratio.

^aIndex group.

^bPer 10 person-years.

^cAdjusted for age, gender, medical history, co-medication, type of surgery, main diagnosis (not Included in model because of low cell count: vancomycin vs. piperacillin ,vancomycin vs. ertapenem, vancomycin vs. daptomycin, and vancomycin vs. cefepime).